Latest COO news and sentiment

How Investors May Respond To Cooper Companies (COO) Analyst Forecasts Of Segment-Driven Earnings And Revenue Growth

Are Wall Street Analysts Bullish on Cooper Companies Stock?

Wall Street analysts are not overly enthusiastic about Cooper Companies (COO) stock, despite a "Moderate Buy" consensus rating from 18 analysts. This sentiment is influenced by the company's annual sales growth, which has lagged behind the healthcare industry average, and its below-average returns on capital. Although analysts expect a 12.4% rise in EPS for the current year, and the stock has a mean price target offering a 6.1% upside, its performance has underperformed the broader market and the State Street Healthcare Select Sector SPDR ETF over the past year.

The Cooper Companies, Inc. (COO) Stock Analysis: Strong Buy Ratings with 6.93% Potential Upside

The Cooper Companies, Inc. (COO), a healthcare sector player specializing in contact lenses and women's health products, currently trades at $76.22 with a potential upside of 6.93% based on analyst consensus. Despite no dividend, the company shows strong revenue growth (7.90%) and robust free cash flow ($424 million), with a forward P/E of 15.26 indicating anticipated earnings growth. Positive analyst sentiment, a low RSI of 32.92, and performance above moving averages suggest a potential buying opportunity for investors focused on medical instruments and supplies.

Here's Why The Cooper Companies (COO) is a Strong Growth Stock

The Cooper Companies (COO) has been identified as a strong growth stock, receiving a "Buy" rating from Zacks Rank and a "B" for its Growth Style Score. The company, which operates in contact lenses and women's health, is forecasted to have 12.4% year-over-year earnings growth for the current fiscal year. Its solid Zacks Rank and top-tier Style Scores make it an attractive option for growth investors.

COO Stock Surges 22% in Past Three Months: What's Driving the Uptrend?

The Cooper Companies (COO) stock has surged 22.2% in the past three months, driven by strong contact lens demand, market-share gains by CooperVision, and a recovery in its CooperSurgical fertility business. While the company faces competition and some regional weakness, its innovative product portfolio and potential strategic review of CooperSurgical position it for continued growth. Analysts maintain a favorable outlook, rating the stock a Zacks Rank #2 (Buy).

NewEdge Wealth LLC Acquires New Shares in The Cooper Companies, Inc. $COO

NewEdge Wealth LLC has acquired 36,043 new shares in The Cooper Companies, Inc. (NASDAQ:COO), valued at approximately $2.6 million, during the second quarter. Several other institutional investors also initiated positions, bringing institutional ownership to 24.39%. Despite mixed analyst sentiment with a consensus "Hold" rating, Cooper Companies surpassed quarterly expectations with $1.21 EPS and $1.08 billion in revenue, while maintaining its fiscal 2026 EPS guidance.

Tocqueville Asset Management L.P. Acquires Shares of 20,952 The Cooper Companies, Inc. $COO

Tocqueville Asset Management L.P. recently purchased a new stake of 20,952 shares in The Cooper Companies, Inc. (NASDAQ:COO), valued at approximately $1,502,000. Other institutional investors also adjusted their holdings in the medical device company. Cooper Companies reported strong Q2 earnings, beating analyst expectations with $1.21 EPS and $1.08 billion in revenue, and analysts have a mixed view on the stock, with an average "Hold" rating.

Deutsche Bank AG Takes $61.20 Million Position in The Cooper Companies, Inc. $COO

Deutsche Bank AG has acquired a significant new position in The Cooper Companies, Inc. (NASDAQ:COO), purchasing 853,483 shares valued at approximately $61.20 million. This acquisition makes Deutsche Bank AG one of several institutional investors to adjust their holdings in the medical device company. Cooper Companies recently reported strong quarterly earnings, exceeding analyst expectations for both EPS and revenue, though its relatively high P/E ratio of 64.54 suggests sensitivity to investor expectations.

Is Cooper Companies (COO) Cheap After Slower Growth Forecasts Raised Valuation Concerns?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Analyst projections of slower revenue growth for Cooper Companies (COO), along with past growth projects that did not clear the healthcare sector's cost of capital, have put the stock's recent underperformance in sharper focus for investors. See our latest analysis for Cooper Companies. Over the past year Cooper Companies has seen some recovery in its share price, with a 90 day share price return of 21.76% and a 1 year total shareholder return of 1.25%. However, the 3 year and 5 year tot

Cooper (COO) Results Versus Estimates: The Bottom-Line Figure Beats Its Comparison in the Latest Reading; Price Move: Shares Move 1.28% Higher in the Current Update - Earnings Growth Forecast

Generation Investment Management LLP Takes $356.30 Million Position in The Cooper Companies, Inc. $COO

Generation Investment Management LLP has acquired a new position in The Cooper Companies, Inc. (NASDAQ:COO), purchasing 4,968,673 shares valued at approximately $356.30 million, making it their 10th largest holding. Several other institutional investors also adjusted their stakes in Cooper Companies, which recently reported strong quarterly earnings of $1.21 EPS, surpassing analyst estimates. Despite a consensus "Hold" rating from analysts, the company's stock has an average target price of $81.64.

Cooper Companies (COO) Following MyDAY Rollout Progress Still Looks Only Modestly Undervalued

Aurora Investment Counsel Acquires Shares of 20,867 The Cooper Companies, Inc. $COO

Aurora Investment Counsel recently purchased 20,867 shares of The Cooper Companies, Inc. (NASDAQ:COO) valued at approximately $1.496 million during the second quarter. Other institutional investors also increased their holdings in the medical device company, with 24.39% of the stock now owned by hedge funds and institutional investors. Despite a "Hold" average analyst rating, the company reported strong earnings, beating consensus estimates, and has a market capitalization of $14.96 billion.

Cooper Companies (COO) Stock Could Be 49% Undervalued As Cash Flow Supports The Case

Cooper Companies (COO) stock presents a valuation debate, with a Discounted Cash Flow (DCF) model suggesting it is 49% undervalued, implying an intrinsic value of $148 per share. However, the stock trades at a P/E ratio of 62.7x, significantly higher than the industry average of 27.2x, leading to a low score on broader valuation checks. The article highlights both bull and bear cases, leaving investors to weigh the strong cash flow potential against the current premium earnings multiple.

COO Stock Surges 22% in Past Three Months: What's Driving the Uptrend?

The Cooper Companies (COO) stock has surged 22.2% in the past three months, driven by strong contact lens demand, recovery in fertility markets, and strategic portfolio optimization. The company reported record revenues and increased EPS, maintaining market share leadership in CooperVision and experiencing growth in CooperSurgical. While facing competition and Asia-Pacific market challenges, its underlying growth profile and potential for strategic changes in CooperSurgical make it an attractive long-term investment.

Cooper Companies (NASDAQ:COO) Stock Crosses Above 200-Day Moving Average - Time to Sell?

Cooper Companies (NASDAQ:COO) recently saw its stock cross above its 200-day moving average, trading at $75.10 against a $71.22 average. The company reported strong quarterly earnings, exceeding expectations with $1.21 EPS and $1.08 billion in revenue, marking a 7.9% year-over-year increase. Analyst sentiment is mixed, with a consensus "Hold" rating and a price target of $81.64, while institutional investors hold 24.39% of the stock.

CooperCompanies stock holds steady after Q3 beats estimates

CooperCompanies (COO) stock held steady after its Q3 earnings beat estimates with $1.21 EPS, surpassing the $1.10 consensus, and revenue grew 7.9% year-over-year. Despite a negative year-to-date performance, analyst targets suggest potential upside, with a consensus of $81.64. The company's diverse business segments, CooperVision and CooperSurgical, contribute to its strong operating base and premium valuation.

Citi Maintains Cooper Companies(COO.US) With Hold Rating, Raises Target Price to $80

Citi has reiterated its Hold rating for Cooper Companies (COO.US) and increased the price target to $80. This adjustment reflects Citi's updated valuation for the company.

Here's Why You Should Add Cooper Companies Stock to Your Portfolio Now

Cooper Companies (COO) shows strong growth potential due to CooperVision's premium lens and myopia-management leadership, coupled with CooperSurgical's robust women's health and fertility segments. Despite near-term challenges like Asia-Pacific weakness and tariff/FX pressures, the company's sustained market-share gains and high-growth franchises position it favorably. Analysts maintain a positive outlook, with expectations of improved earnings and revenue growth in the coming fiscal years.